Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016–March 2019

@article{Peters2019LongActingII,
  title={Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016–March 2019},
  author={Luisa Peters and Amanda Krogmann and Laura von Hardenberg and Katja B{\"o}deker and Viktor B. N{\"o}hles and Christoph U. Correll},
  journal={Current Psychiatry Reports},
  year={2019},
  volume={21}
}
This study was conducted in order to review randomized controlled trial (RCT) data published January 2016–March 2019 on long-acting injectable antipsychotics (LAIs) for schizophrenia. Thirty-one RCTs (primary studies = 7; post hoc analyses = 24; n = 4738) compared LAIs vs. placebo (studies = 11, n = 1875), LAIs vs. oral antipsychotics (OAPs) (studies = 7, n = 658), and LAI vs. LAI (studies = 13, n = 2205). LAIs included two new formulations, aripiprazole lauroxil nanocrystal dispersion and… 
Comparative Efficacy and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the Treatment of Schizophrenia: A Systematic Review and Meta-analysis
  • Seon-Cheol Park, M. Choi, Seung-Hwan Lee
  • Psychology, Medicine
    Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology
  • 2018
TLDR
There is moderate to high level of evidence suggesting that in the treatment of schizophrenia, LAI SGAs have higher efficacy and are associated with higher rates of extrapyramidal syndrome and prolactin-related symptoms.
Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications.
TLDR
Among younger persons, HD was associated with lower rates of efficacy failure than PP, and age-related heterogeneity of antipsychotic treatment effects warrants further investigation and consideration in clinical practice.
Long‐term effectiveness of oral second‐generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‐analysis of direct head‐to‐head comparisons
TLDR
The long‐term risk‐benefit profiles of specific SGAs need to be tailored to individual patients to optimize maintenance treatment outcomes, and different long-term SGA efficacy and tolerability patterns emerged.
Effects of Long-Acting Injectable Paliperidone Palmitate on Clinical and Functional Outcomes in Patients With Schizophrenia Based on Illness Duration.
TLDR
Starting paliperidone LAI significantly improved clinical and functional outcomes in patients with schizophrenia, especially those with shorter duration of illness, suggest that LAI antipsychotic administration may be considered in early-stage schizophrenia for improved outcomes.
Impact of early use of long-acting injectable antipsychotics on functional outcome in first episode psychosis: a 3-year longitudinal study.
TLDR
A naturalistic study suggests a significant protective effect of LAI-AP on extreme residential instability for the most vulnerable patients, but no impact of the first AP administration route on other functional outcomes was observed at 3 years of follow-up.
Correlation between telomere length and efficacy of oral and long-acting injectable antipsychotics on severity and cognitive impairment of schizophrenia.
TLDR
LAI antipsychotics are similar to OAA in decreasing the disorder severity and improving the cognitive impairment in schizophrenia, and patients who have shorter telomere length show greater improvement in the negative PANSS score, suggesting TL holds the potential of predicting antipsychotic drug response in schizophrenia patients.
Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
TLDR
Both PP3M and PP1M formulations exhibited comparable incidence of EPS-related TEAEs, TTO, and TTR in patients with schizophrenia, despite differences in apparent half-life and pharmacokinetic profiles.
Patients’ perspectives on three-monthly administration of antipsychotic treatment with paliperidone palmitate – a qualitative interview study
TLDR
Switching from monthly to three-monthly injections with paliperidone palmitate seems to be experienced as advantageous for patients with schizophrenia.
Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1
TLDR
Findings support wider use of LAIs in patients with schizophrenia/schizoaffective and bipolar disorders beyond the setting of poor adherence and earlier use in the disease course.
The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly
TLDR
Preliminary data currently confirm the maintenance of clinical stability shifting from PP1M to PP3M, with the evaluation of plasma levels of the drug.
...
...

References

SHOWING 1-10 OF 88 REFERENCES
Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.
TLDR
Results from mirror-image studies in patients eligible for clinical use of LAI showed strong superiority of LAIs compared to oral antipsychotics in preventing hospitalization, in contrast to the recent meta-analysis of RCTs, which showed no superiority.
Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.
TLDR
In RCTs, which are less representative of real-world patients than naturalistic studies, pooled LAIs did not reduce relapse compared with OAPs in schizophrenia patients, and studies comparing FGA-LAIs vs second-generation antipsychotics-LAI and LAI vs OAP R CTs in real- world patients are needed.
Mortality Risk Associated With Long-acting Injectable Antipsychotics: A Systematic Review and Meta-analyses of Randomized Controlled Trials.
TLDR
There was no significant difference between LAI-APs and placebo or OAPs regarding all-cause death and death due to suicide and in a subgroup meta-analysis of only short-duration RCTs, pooled LAI -APs exhibited a trend toward lower incidence of all- Cause death than placebo.
Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies
TLDR
The lack of significant superiority of LAIs for hospitalization risk and hospital days needs to be interpreted in the context of naturalistic treatment selection with subsequently greater illness severity/chronicity in LAI-treated patients.
Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial
TLDR
The results of this preliminary study suggest that PPs may improve attention and processing speed more than RLAIs and a replication in a larger and double-blind study is needed.
Comparative Efficacy and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the Treatment of Schizophrenia: A Systematic Review and Meta-analysis
  • Seon-Cheol Park, M. Choi, Seung-Hwan Lee
  • Psychology, Medicine
    Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology
  • 2018
TLDR
There is moderate to high level of evidence suggesting that in the treatment of schizophrenia, LAI SGAs have higher efficacy and are associated with higher rates of extrapyramidal syndrome and prolactin-related symptoms.
An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis.
TLDR
RLAI offers no advantage to patients in early phase of SS disorders, but is likely to be effective and safe for those who may have problems with adherence and may either choose to take it or be prescribed under conditions of external control such as community treatment orders.
...
...